Re-branded as Lineage Cell Therapeutics (NYSE US: LCTX)
BioTime
Ocata Therapeutics
Acquired by Astellas Pharma in 2016 for $379 Million (NY Times’ coverage here)
XO1
Acquired by Janssen Pharmaceuticals, a Johnson & Johnson company, in 2015